Loss of MIG6 accelerates initiation and progression of mutant epidermal growth factor receptor–driven lung adenocarcinoma

Cancer Discovery

Volumn 5, Issue 5, 2015, Pages 534-549

  Maity, Tapan K ^a   Venugopalan, Abhilash ^a   Linnoila, Ilona ^a   Cultraro, Constance M ^a   Giannakou, Andreas ^b,e   Nemati, Roxanne ^a   Zhang, Xu ^a   Webster, Joshua D ^a,f   Ritt, Daniel ^c   Ghosal, Sarani ^a   Hoschuetzky, Heinz ^d   Mark Simpson, R ^a   Biswas, Romi ^a   Politi, Katerina ^b,g   Morrison, Deborah K ^c   Varmus, Harold E ^b,h   Guha, Udayan ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d nanoTools   (Germany)

^e PFIZER INC   (United States)

^f GENENTECH INC   (United States)

^g YALE CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PEPTIDES AND PROTEINS; PROTEIN KINASE B; PROTEIN MIG6; S6 KINASE; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; MIG-6 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA TRANSFECTION; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CELL TRANSFORMATION; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; GENE DELETION; GENE EXPRESSION; GENETICS; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEOMICS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE DELETION; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84980037538     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0750     Document Type: Article

References (60)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306–11.
4. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–46.
5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786–92.
6. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–43.
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932–7.
9. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2: 922–33.
10. Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011; 1: 608–25.
11. de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 2014; 4: 606–19.
12. Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006; 355: 213–5.
13. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
14. T homson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65: 9455–62.
15. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010; 30: 2513–7.
16. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852–60.
17. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012; 109: E2127–33.
18. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25–38.
19. Greulich H, Chen T-H, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. Plos Med 2005; 2: e313.
20. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005; 65: 8968–74.
21. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291–310.
22. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190–203.
23. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105: 692–7.
24. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer–specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008; 105: 14112–7.
25. Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 2000; 20: 7735–50.
26. Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, Bonventre JV, et al. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 2000; 275: 17838–47.
27. Zhang YW, Vande Woude GF. Mig-6, signal transduction, stress response and cancer. Cell Cycle 2007; 6: 507–13.
28. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006; 12: 568–73.
29. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, et al. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 2010; 107: 6912–7.
30. Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 2007; 26: 269–76.
31. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007; 450: 741–4.
32. Frosi Y, Anastasi S, Ballaro C, Varsano G, Castellani L, Maspero E, et al. A two-tiered mechanism of EGFR inhibition by RALT/ MIG6 via kinase suppression and receptor degradation. J Cell Biol 2010; 189: 557–71.
33. Nagashima T, Ushikoshi-Nakayama R, Suenaga A, Ide K, Yumoto N, Naruo Y, et al. Mutation of epidermal growth factor receptor is associated with MIG6 expression. FEBS J 2009; 276: 5239–51.
34. Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, et al. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 2009; 136: 3347–56.
35. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to downregulation of the receptors. Genes Dev 2006; 20: 1496–510.
36. Perl A K, Tichelaar JW, Whitsett JA. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res 2002; 11: 21–9.
37. Kim TH, Franco HL, Jung SY, Qin J, Broaddus RR, Lydon JP, et al. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 2010; 29: 3770–80.
38. Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick H, et al. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell 2012; 23: 547–59.
39. Xie B, Zhao L, Chen H, Jin B, Mao Z, Yao Z. The mitogen-inducible gene-6 is involved in regulation of cellular senescence in normal diploid fibroblasts. Biol Cell 2013; 105: 488–99.
40. Milewska M, Kolch W. Mig-6 participates in the regulation of cell senescence and retinoblastoma protein phosphorylation. Cell Signal 2014; 26: 1870–7.
41. Anastasi S, Castellani L, Alema S, Segatto O. A pervasive role for MIG6 in restraining cell proliferation. Cell Death Differ 2013; 21: 345–347.
42. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725–30.
43. Collado M, Serrano M. The power and the promise of oncogeneinduced senescence markers. Nat Rev Cancer 2006; 6: 472–6.
44. Wang Z, Longo PA, Tarrant MK, Kim K, Head S, Leahy DJ, et al. Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 2011; 18: 1388–93.
45. Anastasi S, Baietti MF, Frosi Y, Alema S, Segatto O. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene 2007; 26: 7833–46.
46. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012; 40: D261–70.
47. Wang Z, Raines LL, Hooy RM, Roberson H, Leahy DJ, Cole PA. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. ACS Chem Biol 2013; 8: 2372–6.
48. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–37.
49. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314: 3093–106.
50. Hendriks BS, Griffiths GJ, Benson R, Kenyon D, Lazzara M, Swinton J, et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. IEE Proc Syst Biol 2006; 153: 457–66.
51. Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 3843–50.
52. Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, et al. Association with HSP90 inhibits Cbl-mediated downregulation of mutant epidermal growth factor receptors. Cancer Res 2006; 66: 6990–7.
53. Padron D, Sato M, Shay JW, Gazdar AF, Minna JD, Roth MG. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and downregulation but are efficiently internalized. Cancer Res 2007; 67: 7695–702.
54. Walsh AM, Lazzara MJ. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells. J Cell Sci 2013; 126: 4339–48.
55. Walsh AM, Lazzara MJ. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations. Integr Biol (Camb) 2014; 6: 312–23.
56. Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, et al. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS ONE 2013; 8: e68966.
57. Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, et al. The TGFbeta-miR200-MIG6 pathway orchestrates the EMTassociated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 2014; 74: 3995–4005.
58. Li Z, Dong Q, Wang Y, Qu L, Qiu X, Wang E. Downregulation of Mig-6 in non–small-cell lung cancer is associated with EGFR signaling. Mol Carcinog 2012; 51: 522–34.
59. Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, et al. Thyroid-specific knockout of the tumor suppressor mitogeninducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-kappaB activity. Surgery 2011; 150: 1295–302.
60. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012; 18: 1947–53.